The central role of cDC1 in antitumor immunity and in cancer therapy is well documented.18 19 25 53 One crucial feature is the production of the chemokine CXCL9 by cDC1 in the TME facilitating the formation of DC-T cell clusters and cross-presentation of tumor antigens within those niches, which is essential for functional aspects of intratumoral CD8+ T cells and tumor immune control.26 In our study, the absence of cDC1 in Batf3-deficient mice shortened the survival of mice in response to BRAFi therapy but did not cause a complete failure of treatment. This evidence concerns the gene CXCL9 and cancer.